title: [LIRAGUTIDE AT A DOSE OF 3.0 MG (SAXENDA): NEW INDICATION FOR THE TREATMENT OF OBESITY].
abstract: Liraglutide is an analogue of Glucagon-Like Peptide-1 (GLP-1) already indicated under the trade name of Victoza for the treatment of type 2 diabetes, at usual doses of 1.2 or 1.8 mg as once daily subcutaneous injection. It is henceforth indicated at a dose of 3.0 mg, also as once daily subcutaneous injection, for the treatment of obesity or overweight with comorbidities under the trade name of Saxenda, in combination with diet and exercise. Besides a specific action on the endocrine pancreas, mainly responsible for the antihyperglycaemic effect, liraglutide helps controlling appetite at the hypothamalic level. A specific programme of controlled trials (especially SCALE studies) demonstrated both efficacy and safety of the 3.0 mg dose of liraglutide in obese or overweight patients with various comorbidities.
authors.forename: A J
authors.initials: AJ
authors.lastname: Scheen
mesh_terms: D003131:Combined Modality Therapy; D015897:Comorbidity; D004304:Dosage Forms; D058492:Drug Repositioning; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069450:Liraglutide / Q000008:administration & dosage* / Q000009:adverse effects; D009765:Obesity / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy* / Q000453:epidemiology; D012891:Sleep Apnea Syndromes / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology
chemical_list: D004304:Dosage Forms; D007004:Hypoglycemic Agents; D000069450:Liraglutide